Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat

British Journal of Pharmacology

Volumn 131, Issue 6, 2000, Pages 1179-1187

  Álvarez De Sotomayor, Maria ^a   Herrera, Maria Dolores ^a   Marhuenda, Elisa ^a   Andriantsitohaina, Ramaroson ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b CNRS   (France)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase; Cyclo oxygenase products; Endothelium; Nitric oxide; Rat aorta; Simvastatin; Small mesenteric artery; Tyrosine kinase

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; GENISTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSANOID; INDOMETACIN; MEVALONIC ACID; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SIMVASTATIN; SUPEROXIDE DISMUTASE; THROMBOXANE RECEPTOR BLOCKING AGENT; VAPIPROST;

ANIMAL EXPERIMENT; AORTA; ARTERY CONSTRICTION; ARTERY RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; INHIBITION KINETICS; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE RELAXATION; SUPERIOR MESENTERIC ARTERY; VASODILATATION;

EID: 0033680381     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703668     Document Type: Article

References (40)

1. Genistein, a specific inhibitor of tyrosine-specific protein kinases
2. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats
3. Nitric oxide production and endothelium-dependent vasorelaxation induced by wine polyphenols in rat aorta
4. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy
5. Cardiovascular effects of lovastatin in normotensive and spontaneously hypertensive rats
6. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity
7. Protein lipidation in cell signaling
8. Alterations of cyclo-oxygenase products and NO in responses to angiotensin II of resistance arteries from the spontaneously hypertensive rat
9. Effects of growth factors on cell cycle arrest in dolichyl phosphate-depleted cultures
10. 2+ stores and protein synthesis in human endothelial cells
11. 2+ mobilization in vascular smooth muscle cells
12. Farnesylated-γsubunit of photoreceptor G protein indispensable for GTP-binding
13. Regulation of the mevalonate pathway
14. 2+/EDRF signalling are due to generation of superoxide anions
15. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo oxygenase-2
16. Effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
17. 2+ entry for endothelial nitric oxide production
18. Hydrogen peroxide induces intracellular calcium oscillations in human aortic endothelial cells
19. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
20. Erythromicin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
21. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
22. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
23. Grapefruit juice-simvastatin interaction: Effect of serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors
24. Regulation of phosphorylation pathways by p21 GTPases: The p21 Ras-related Rho subfamily and its roles in phosphorylation signalling pathways
25. Spontaneously hypertensive rats are resistant to the development of hypercholesterolemia
26. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular synthesis in vascular disease
27. Alteration by lipopolysaccharide of the relationship between intracellular calcium levels and contraction in rat mesenteric artery
28. Simvastatin: A review of its pharmacology and clinical use
29. Role of tyrosine phosphorylation of phospholipase C gamma 1 in the signalling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblast
30. 2- response in rat A10 vascular smooth muscle cells
31. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
32. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
34. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation
35. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, an HMG-CoA reductase inhibitor
36. Beneficial effects of cholesterol-lowering therapy on the coronary artery diseases
37. Statins do more than just lower cholesterol
38. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitor through attenuation of endothelial superoxide anion formation
39. N(G)-nitro-L-arginine contracts vascular smooth muscle by an endothelium-independent mechanism
40. 2+ channels in rat islet β-cells